Navigation Links
How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

Dr Alan Ramsay will present findings of a study in patients with Chronic Lymphocytic Leukemia that will contribute to the design of immunotherapeutic strategies leading to the killing of cancer cells at the 17th Congress of the European Hematology Association in Amsterdam.

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells. T cell activity is tightly regulated by signaling at the contact site (referred to as the "immune synapse") with a target cell. However, the ability of cancer cells to evade T cell recognition and destruction is an emerging hallmark of disease progression. We have previously demonstrated that tumour cells induce impaired T cell immune synapse signaling and killing function in chronic lymphocytic leukaemia patients. The aim of this study was to identify the molecules that mediate this T cell defect in cancer. We designed and performed laboratory assays to identify that the inhibitory molecules CD200, CD270 (HVEM), CD274 (PD-L1), and CD276 (B7-H3) are co-opted by leukaemia cells to induce impaired T cell synapse signalling. We further show that these inhibitory molecules are highly active and mediate impaired T cell function in both haematological malignancies (including follicular lymphoma) and solid carcinoma cells. Of clinical relevance, we demonstrate that the immunomodulatory drug lenalidomide prevented induction of the T cell activation defect by down-regulating tumour cell inhibitory molecule expression and activity. These results establish a novel immune evasion mechanism whereby cancer cells exploit multiple inhibitory signalling pathways to suppress T cell synapse signalling. These pre-clinical findings should help contribute to the design of immunotherapeutic strategies to specifically block these inhibitory molecules in cancer and to repair T cell recognition and killing of cancer cells.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New method for producing precursor of neurons, bone and other important tissues from stem cells
2. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
3. Notre Dame researchers develop paint-on solar cells
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
6. In solar cells, tweaking the tiniest of parts yields big jump in efficiency
7. Mesenchymal Stem Cells Have New Cell Culture Environment
8. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
9. Scientists Discover How a Bacterial Pathogen Breaks Down Barriers to Enter and Infect Cells
10. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
11. Study dusts sugar coating off little-known regulation in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):